The global nucleic acid isolation and purification market size was valued at USD 5.11 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 10.06% from 2023 to 2030. The market expansion is fueled by several factors such as the rise in adoption of sequencing platforms in clinical diagnostics, growth in genomics & enzymology-based research, and increase in investments in R&D. In addition, the significance potential of molecular biology and advancement in precision medicine are further augmenting market growth. Increasing efforts of market participants to strengthen the capabilities of precision medicine for effective disease prognosis are facilitating market expansion. For instance, in September 2022, Avesthagen Limited launched the first fully integrated personalized genetic testing service AVEN Diagnostics. This service utilizes advanced technologies to advance the diagnosis process.
Privatization of the production of therapeutics with commercial potential, such as vaccines and peptide-based drugs, to suffice healthcare needs is driving the demand for large-scale separation instruments Thus, the nucleic acid isolation and purification industry exhibits lucrative growth potential. In addition, increasing automation in the industry, technological advancements, availability of benchtop instruments, and increasing investments from pharma companies has further supported the market. For instance, in April 2022 Zymo Research and Star Array announced a strategic investment to acquire Star Array, a biomedical company in Singapore. This strategy allowed Zymo to combine its nucleic acid purification technology with Star Array’s automation technique to expand its diagnostics portfolio.
Rapidly evolving biotechnological applications in various industries, such as food processing, agriculture, recycling & waste management, and energy & environmental, are projected to drive the adoption of nucleic acid isolation and purification. Also, factors such as growing pharmaceutical production, leveraged support for the biotechnology industry from the government, support in the regulatory framework, continuous R&D efforts, and ongoing research activities. These factors are expected to drive the market in the near future. For instance, in June 2022 Molzym received a fourth round of funding to strengthen its offering in microbial DNA isolation technology.
Moreover, increasing collaboration and expansion undertaken by leading market players to bolster their nucleic acid extraction modalities is another factor propelling industry growth. For instance, in April 2020 QIAGEN and Gilson collaborated to make manual nucleic acid extraction more efficient and reproducible. This collaboration integrated QIAGEN’s manual nucleic acid extraction kits and TRACKMAN Connected digital bench tool to enhance yield as well as efficiency.
Furthermore, Formalin-fixed, paraffin-embedded (FFPE) samples play a crucial role in determining the molecular correlates of carcinogenesis. However, the labor-intensive process of extracting nucleic acids from these samples and the potential for nucleic acid damage pose significant obstacles, limiting the use of FFPE samples. To address these challenges, companies are introducing novel isolation kits to facilitate the recovery of nucleic acids. For instance, in September 2022, Akadeum Life Sciences, Inc. announced the early access launch of a large-scale cell isolation kit for leukopaks. This research-use-only (RUO) kit aims to address workflow challenges in the laboratory.
The product segment is bifurcated into Kits & Reagents, and instruments. Kits & reagents dominated the nucleic acid isolation and purification market in 2022, with a revenue share of 76.28%. The market comprises of a wide range of DNA and RNA isolation/extraction and purification kits for preparing samples and libraries. These kits are used in the extraction of nucleic acids from tissue, blood, cells, and plants. For instance, Thermo Fisher Scientific offers PrepSEQ 1-2-3 Mycoplasma Nucleic Acid Extraction Kit designed for the extraction of mycoplasma genomic DNA from samples. Also, the company offers the MagMAX CORE Nucleic Acid Purification Kit, which is utilized for the purification and mechanical lysis of nucleic acids. The demand for kits used in the isolation and purification of nucleic acids is on the rise, driven by the increasing number of research studies focused on comprehending genome-based diseases such as Huntington’s disease, polyketonuria, and others.
Whereas the instrument segment is projected to register the fastest growth rate of 12.19% in the coming years. This high growth is attributed to technological advancements in instruments, robust demand from end-users, and increased demand for automated NAIP instruments. Also, recent product launches from manufacturers are another factor supporting segment expansion. For instance, in May 2023 One BioMed launched a fully integrated platform for automated high molecular weight DNA extraction.
The type segment is divided into DNA isolation & purification and RNA isolation & purification. The RNA isolation & purification segment held the largest share of 53.88% in 2022. RNA isolation & purification are used in a variety of molecular biology applications. In addition, isolation & purification of high-quality RNA molecules lead to the success of many breakthroughs like cloning, reverse transcription for cDNA synthesis, RT-PCR (which became widely crucial during the COVID-19 pandemic), RNA-seq, etc.
The increasing application in diagnostics and the rise in the use of purified mRNA for the construction of the cDNA library are projected to drive segment growth. These libraries have various applications such as gene expression profiling, sequencing, and clinical diagnostics. Moreover, the availability of a broad range of kits for the extraction and processing of viral and bacterial RNA is further contributing to segment growth.
The DNA isolation & purification segment is anticipated to register significant growth at 11.71% CAGR. The segment growth is attributed to rising research activities and supportive government legislation. In addition, continuous advancements in nucleic acid isolation and purification technologies and the growing interest of pharmaceutical and biotechnology companies in DNA purification are further supporting industry expansion.
The application segment is further segmented into precision medicine, diagnostics, drug discovery & development, agriculture and animal research, and other applications. Diagnostics dominated the application segment with a revenue share of 33.49% in 2022. The large revenue share of the segment can be attributed to the rising application of DNA and RNA isolation for the identification of pathogens in routine sample processing. For instance, PCR techniques are widely adopted for the rapid detection of microorganisms, which was previously not possible with traditional microbiological detection methods.
Moreover, companies are launching new diagnostic solutions for identifying emerging infections and diseases. For instance, in May 2023 Menarini Diagnostics is all set to introduce its fully automated MDx platform to conduct respiratory infection tests. Thus, the launch of new products for diagnosing various new emerging infections is further contributing to segment growth.
The drug discovery & development segment is projected to witness a lucrative growth rate of 10.82% over the forecast period. Growth in the segment can be primarily attributed to robust investments in pharmaceutical and biotechnology companies for the development of novel drugs. Nucleic acid purification methods are largely employed in various steps of drug discovery, target identification, and testing.
The method segment is further sub-segmented into column-based, magnetic beads, reagent-based, and others. Among these, the magnetic beads method segment held the largest revenue share of the market in 2022 with a share of 38.54%. The growing adoption of magnetic beads is owing to the advantage that it provides to researchers and scientists with improved assay performance and better isolation and purification of DNA and RNA.
In recent years, functionalized magnetic beads have been used along with suitable buffer systems for rapid and efficient extraction. This method reduces the requirement of centrifugation which usually results in the breaking of nucleic acids. Hence, such a positive aspect of this technology provides automated extraction with minimal requirement of centrifugation for nucleic acid isolation steps.
The column-based segment is expected to register a steady growth rate of 9.51% in the coming years. Silica columns are mainly preferred for getting higher-quality nucleic acids in less time. Moreover, these techniques can be incorporated in spin columns that possess various benefits such as fast process, higher yield, cost-effectivity, and compatibility with automated instruments. Therefore, these methods are widely adopted in DNA extraction processes.
The end-use segment is further segmented into academic research institutes, pharmaceutical & biotechnology companies, contract research organizations, hospitals and diagnostic centers, and other end-uses. Hospitals and diagnostics centers held the largest share of 33.63% in 2022 as the use of nucleic acids in hospitals and diagnostic centers has increased due to their wide range of applications in healthcare segments, such as genetic fingerprinting, prenatal testing, and liquid biopsies. DNA and RNA isolation and purification techniques are considered as efficient tools for the diagnosis of certain genetic diseases-sickle cell anemia, hemophilia A, fragile x syndrome, cystic fibrosis, Down’s syndrome, and Tay-Sachs disease to name a few. Thus, the availability of such technologies at low prices is projected to propel their adoption rate in diagnostic centers and hospitals.
Pharmaceutical and biotechnology companies are expected to register the fastest growth rate of 10.40% during the projected period. The rising adoption of advanced technologies by companies to develop various novel therapies is projected to drive segment growth. As, nucleic acid purification and isolation is a critical step in drug discovery and development hence, higher demand for DNA extraction kits and instruments in pharma and biotech companies is anticipated drive segment growth forward.
North America held the largest share of 36.62% in the year 2022. Factors such as the presence of a large number of market players in the region and various initiatives undertaken by them are projected to drive the regional market. In addition, leveraged government support, the presence of a favorable regulatory framework, and consistent R&D efforts are expected to drive the market in the near future. The North America market is expected to grow at a CAGR of 9.90% during the forecast period.
Asia Pacific is projected to register the fastest growth throughout the forecast period. Growing patient population, ongoing developments, private-public collaborations, and supportive government initiatives have offered immense opportunities for the growth of the Asia Pacific market. Also, various leading companies operate in the region and offer a broad range of kits for the isolation and purification of genomic and plasmid DNA from a wide variety of samples, including serum, blood, cells, tissue, forensic, and plant samples. More such efforts are expected to contribute toward the growth of the regional market.
The nucleic acid isolation and purification market is moderately fragmented with the presence of a large number of well-established players. These players are undertaking several initiatives to expand their DNA or RNA extraction instruments and kits. For instance, in May 2023, One BioMed launched X8 HMW DNA Cartridge Kits for the automated isolation of high molecular weight nucleic acid for use in genome assembly. Some prominent players in the global nucleic acid isolation and purification market include:
Thermo Fisher Scientific, Inc.
F. Hoffmann-La Roche Ltd
Bio-Rad Laboratories, Inc.
Takara Bio Inc.
New England Biolabs
Norgen Biotek Corp.
PCR Biosystems, Inc.
Apical Scientific Sdn. Bhd
MACHEREY-NAGEL GmbH & Co. KG
In July 2023, Promega Corporation announced a joint marketing agreement with INOVIQ to co-market EXO-NET exosome isolation purification of nucleic acid solutions
In September 2022, Takara Bio Inc. launched the latest Contract Development and Manufacturing Organization (CDMO) service. This includes the purification and isolation of nucleic acid for the vector construction
In September 2022, Illumina Inc. launched the NovaSeqTM X Series to accelerate genomic discoveries, and improve the human health. This is an advancement in the genomics field that involves nucleic acid sequence technologies
In August 2022, New England Biolabs® introduced the faustovirus capping enzyme, an mRNA solution used in mRNA synthesis. This enzyme is useful for the manipulation and purification of nucleic acid for therapeutic applications
In June 2021, Bio-Rad Laboratories Inc. partnered with Seegene Inc. to develop molecular diagnostic testing for products. This includes amplification and isolation of nucleic acid collected from patient samples to diagnose harmful diseases
In April 2021, AutoGen Inc. and Isohelix signed a collaborative supply agreement to supply RNA and DNA purification and sampling products, and nucleic acid extraction automation
In April 2021, LGC Limited launched the SARS-CoV-2 quality-based solution for the testing of antigen with the use of nucleic acid isolation and purification process
In April 2021, Thermo Fisher Scientific Inc. launched the Thermo Scientific KingFisher Apex Purification System. It is a nucleic acid isolation that automates the extraction of RNA, DNA, cells, and proteins from different samples
Market size value in 2023
USD 5.73 billion
Revenue forecast in 2030
USD 11.21 billion
CAGR of 10.06% from 2023 to 2030
Base year for estimation
2018 - 2021
2023 - 2030
Revenue in USD million, CAGR from 2023 to 2030
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Product, type, method, application, end-use, region
North America; Europe; Asia Pacific; Latin America; MEA
U.S.; Canada; Germany; U.K.; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; South Korea; Australia; Thailand; Brazil; Mexico, Argentina; South Africa; Saudi Arabia, UAE; Kuwait
Key companies profiled
QIAGEN; ThermoFisher Scientific Inc.; Illumina Inc; Danaher; F. Hoffmann La Roche Ltd; Merck KGGA; Agilent Technologies Inc.; Bio-Rad Laboratories; Takara Bio Inc; Promega Corporation; New England Biolabs; LGC limited; ABCAM PLC; Norgen Biotek Corp; Autogen Inc; Biogenuix, PCR Biosystems; Maggenome; Axon Scientific Sdn. Bhd; Macherey-Nagel GmbH & Co. KG
Free report customization (equivalent up to 8 analysts' working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at global, regional, & country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the global nucleic acid isolation and purification market report based on product, type, method, application, end-use, and region:
Product Outlook (Revenue, USD Million, 2018 - 2030)
Kits & Reagents
Type Outlook (Revenue, USD Million, 2018 - 2030)
DNA Isolation & Purification
Genomic DNA Isolation & Purification
Plasmid DNA Isolation & Purification
Viral DNA Isolation & Purification
RNA Isolation & Purification
miRNA Isolation & Purification
mRNA Isolation & Purification
Total RNA Isolation & Purification
Application Outlook (Revenue, USD Million, 2018 - 2030)
Drug Discovery & Development
Agriculture and Animal Research
Method Outlook (Revenue, USD Million, 2018 - 2030)
End-use Outlook (Revenue, USD Million, 2018 - 2030)
Academic Research Institutes
Pharmaceutical & Biotechnology Companies
Contract Research Organizations
Hospitals and Diagnostic Centers
Regional Outlook (Revenue, USD Million, 2018 - 2030)
Middle East and Africa (MEA)
b. The global nucleic acid isolation and purification market size was estimated at USD 5.11 billion in 2022 and is expected to reach USD 5.73 billion in 2023.
b. The global nucleic acid isolation and purification market is expected to witness a compound annual growth rate of 10.06% from 2023 to 2030 to reach USD 11.21 billion by 2030.
b. Kits and reagents accounted for the largest share in 2022 due to the wide availability of robust kits for isolation of DNA or RNA from the given sample contributes to the dominance of this segment.
b. Some key players operating in the nucleic acid isolation and purification market include QIAGEN; Illumina, Inc.; Danaher; F. Hoffmann-La Roche Ltd.; Merck KGaA; Thermo Fisher Scientific, Inc.; Agilent Technologies; Bio-Rad Laboratories, Inc.; GE Healthcare; Promega Corporation; and Norgen Biotek Corp.
b. Expanding pipeline for RNA therapeutics, plummeting sequencing cost, and growing popularity of nucleic acid-based diagnostics are some key driving factors of the nucleic acid isolation & purification market.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
"The quality of research they have done for us has been excellent."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.